International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line

Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A

Issue: Jan/Feb 2019 - Volume 23, Number 1
View All Articles in Issue

Page(s): 32-33

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: Stephen R. Snow, Esq., Robert W. Stannard, Esq., Jennifer Bellis, Esq., Carrie A. Moss, Esq., U.S. Food and Drug Administration, FDA, pharmacy inspection exemption, documentation, pharmacy records

Related Categories: LEGAL, QUALITY CONTROL

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Allen Loyd V Jr	Nov/Dec 2023 Pg. 474-481
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Allen Loyd V Jr	Jul/Aug 2007 Pg. 350-351
U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk Brunner Scott	May/Jun 2020 Pg. 198-199
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1 Martin Matt	Sep/Oct 2018 Pg. 401-404
Drugs Banned for Use in Food Animals: An Explanation Davidson Gigi S	Mar/Apr 2001 Pg. 101-103
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 2 Allen Loyd V Jr	Sep/Oct 2007 Pg. 438-439
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
Return to Top